Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült Államok2. fázis

Repurposing Semaglutide for the Treatment of Cocaine Use Disorder

A legfontosabb adatok

Ki végzi
The University of Texas Health Science Center, Houston
Hol
Houston (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
75 fő, tervezett
Kezdés
2026. jan. 15.
Várható befejezés
2029. febr. 28.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Semaglutide
  • Placebo
  • cognitive behavioral therapy (CBT).
A regiszteradat frissítve
2026. március 19.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 34 feltétel megnézéseKevesebb

Ki vehet részt

  • Ability to provide informed consent before any study-related activity, willing to comply with all study procedures, and be available for the duration of the study
  • Meet Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM 5) diagnostic criteria for CUD and report recent cocaine use (verified by at least one positive urine drug screen (UDS) for the cocaine metabolite benzoylecgonine (BE), during intake)
  • Have body mass index (BMI) of ≥25 kg/m2
  • Agree (if the participant is female and of child-bearing potential) to use effective contraceptive methods, unless the participant's male partner(s) is surgically sterile (underwent vasectomy). Acceptable contraceptives include oral contraceptives, contraceptive sponge, patch, double barrier (diaphragm/spermicidal or condom/spermicidal), intrauterine contraceptive system, etonogestrel implant, medroxyprogesterone acetate contraceptive injection, complete abstinence from sexual intercourse, and/or hormonal vaginal ring. Contraceptive measures sold for emergency use after unprotected sex are not acceptable methods for routine use. Women of child-bearing potential must provide negative urine pregnancy test prior to randomization. Note: A woman is considered fertile (of childbearing potential) following menarche and until becoming postmenopausal unless permanently sterile. Women in the following categories are not considered a woman of childbearing potential: premenarcheal, premenopausal female with one of the following: documented hysterectomy, documented bilateral salpingectomy, documented bilateral oophorectomy. Postmenopausal female is defined as no menses for 12 months without an alternative medical cause. Females on HRT and whose menopausal status is in doubt will be required to use one of the nonhormonal highly effective contraception methods if they wish to continue their hormone replacement therapy (HRT) during the trial
  • Have a medical and psychiatric history and a brief physical examination demonstrating no clinically significant contraindications for study participation, in the judgment of the Study Physician and the Principal Investigator
  • Be able to provide the names of at least 2 persons who can consistently locate their whereabouts

Ki nem vehet részt

  • Gained/lost ≥4.5 kg (10 lb.) over the past 6 months (prior to screening)
  • Currently using sincalide, sulfonylureas, insulin and insulin products, or medication used for weight management (i.e., orlistat, naltrexone-bupropion, liraglutide, semaglutide, tirzepatide, phentermine, topiramate, benzphetamine, diethylpropion, phendimetrazine)
  • Any otherwise not specified concomitant medication that could compromise participant safety or treatment in the opinion of the Study Physician and/or the PIs; General Exclusions
  • Surgery scheduled for the duration of the trial, except for minor surgical procedures, in the opinion of the PI and/or the Study Physician
  • Personal or first-degree relative(s) history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2)
  • Severe gastrointestinal disease (i.e., severe gastroparesis)
  • History of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed
  • History of severe cardiovascular disease
  • History of retinopathy
  • Known or suspected hypersensitivity to semaglutide, excipients, or related products
  • History of seizure or elevated risk of seizure
  • Have any medical illness or condition which in the opinion of the PI and/or the Study Physician would preclude safe and/or successful completion of the study
  • Any foreseeable procedure requiring general anesthesia or deep sedation; Psychiatric/Substance Use Exclusions
  • Current ≥ moderate substance use disorder aside from alcohol, nicotine, or marijuana, or a Substance Use Disorder (SUD) requiring medical detoxification (e.g., alcohol, opioid, benzodiazepine)
  • Have any psychiatric illness or condition which in the opinion of the PI and/or the Study Physician would preclude safe and/or successful completion of the study; Weight-Related Exclusions
  • Uncontrolled thyroid disease at screening; Medication-Related Exclusions
  • Type 1 or type 2 diabetes mellitus (previously diagnosed or indicated by HbA1C ≥48 mol/mol (6.5%) as measured at screening)
  • End stage renal disease (ESRD, previously diagnosed or indicated by estimated glomerular filtration rate (eGFR) value of eGFR < 15 ml/min/1.73 m2 at screening)
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3 times the upper limit of normal range at screening
  • Medical Exclusions
  • History or presence of chronic pancreatitis or recent acute pancreatitis
  • Systolic blood pressure (SBP) >180 mmHg and/or diastolic blood pressure (DBP) >105 mmHg)
  • Women who are currently pregnant, or plan to become pregnant, or lactating, or of childbearing potential and are not using medically accepted forms of contraception
  • Current or recent suicidal ideation
  • Homicidal ideation that requires immediate attention
  • Current, anticipated, or pending enrollment in another addiction treatment program and/or research study that could potentially affect participant safety and/or the study data/design as determined by the Principal Investigator and/or Study Physician
  • Not planning to live in the area for the duration of the trial
  • Unable to communicate (read, write, and speak) fluently in English

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • The University of Texas Health Science Center at HoustonHouston, Egyesült ÁllamokContact: Luba Yammine, PhDRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this study is to evaluate semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), in combination with cognitive behavioral therapy (CBT) for the treatment of cocaine use disorder (CUD). This project is part of the NIH Helping to End Addiction Long-term (HEAL) initiative (https://heal.nih.gov/).

A vizsgálat 2 csoportja

  • SemaglutideA vizsgált kezelés

    Kezelés: Semaglutide és cognitive behavioral therapy (CBT).

  • PlaceboPlacebo, összehasonlításként

    Kezelés: Placebo és cognitive behavioral therapy (CBT).

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Repurposing Semaglutide for the Treatment of Cocaine Use Disorder: a Pilot Mechanistic Study
Publikációk
A regiszteradat frissítve
2026. március 19.